D0629
3,5-ジヨード-L-チロニン
thyroid hormone analog
別名:
3,5-T2, 3,5-ジヨード-4-(4-ヒドロキシフェノキシ)-L-フェニルアラニン, O-(4-ヒドロキシフェニル)-3,5-ジヨード-L-チロシン
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C15H13I2NO4
CAS番号:
分子量:
525.08
UNSPSC Code:
41116107
NACRES:
NA.26
PubChem Substance ID:
EC Number:
213-867-7
Beilstein/REAXYS Number:
2707891
MDL number:
InChI key
ZHSOTLOTTDYIIK-ZDUSSCGKSA-N
InChI
1S/C15H13I2NO4/c16-11-5-8(7-13(18)15(20)21)6-12(17)14(11)22-10-3-1-9(19)2-4-10/h1-6,13,19H,7,18H2,(H,20,21)/t13-/m0/s1
SMILES string
N[C@@H](Cc1cc(I)c(Oc2ccc(O)cc2)c(I)c1)C(O)=O
assay
≥99% (HPLC)
form
powder
technique(s)
ligand binding assay: suitable
color
white to off-white
mp
255 °C
storage temp.
−20°C
Quality Level
類似した製品をお探しですか？ 訪問 製品比較ガイド
関連するカテゴリー
Biochem/physiol Actions
3,5-ジヨード-L-サイロニン（T(2)）は、恒常性維持、脂質代謝、およびインスリン抵抗性などのプロセスに影響を及ぼす遺伝子活動を制御するヨウ素化サイロニンホルモンです。
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 3
保管分類
11 - Combustible Solids
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
名称等を表示すべき危険物及び有害物
ishl_indicated
名称等を通知すべき危険物及び有害物
ishl_notified
D0629-5G:4548173996233 + D0629-VAR: + D0629-1G: + D0629-500MG:4548173996226 + D0629-BULK: + D0629-100MG:
jan
Maria Moreno et al.
Thyroid : official journal of the American Thyroid Association, 18(2), 239-253 (2008-02-19)
The processes and pathways mediating the intermediary metabolism of carbohydrates, lipids, and proteins are all affected by thyroid hormones (THs) in almost all tissues. Particular attention has been devoted by scientists to the effects of THs on lipid metabolism. Among
C J Huang et al.
Journal of molecular and cellular cardiology, 31(4), 881-893 (1999-05-18)
We previously reported that T3(3,3',5-triiodo-L-thyronine) acutely increases sodium currents (INa) in neonatal rat myocytes. Here we compare the effects of several thyroid hormone analogs, including T4(3,3',5,5'-tetraiodo-L-thyronine), rT3(3,3',5'-triiodo-L-thyronine), D-T3(3,3',5-triiodo-D-thyronine), 3,5-T2(3,5-diiodo-L-thyronine), DIT (3,5-diiodo-L-tyrosine), MIT (3-monoiodo-L-tyrosine), tetrac (3,3',5,5'-tetraiodo-thyroacetic acid), triac (3, 3',5-triiodo-thyroacetic acid)
Anna M Giudetti et al.
Endocrinology, 146(9), 3959-3966 (2005-06-04)
Short-term effects of 3,5-l-diiodothyronine (T2) on lipid biosynthesis were studied in cultured hepatocytes from hypothyroid rats. A comparison with the effects of T3 was routinely carried out. After T2 addition to cell cultures, a distinct stimulation of fatty acid and
Maria Moreno et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 25(10), 3312-3324 (2011-06-15)
The worldwide prevalence of obesity-associated pathologies, including type 2 diabetes, requires thorough investigation of mechanisms and interventions. Recent studies have highlighted thyroid hormone analogs and derivatives as potential agents able to counteract such pathologies. In this study, in rats receiving
Elena Grasselli et al.
Journal of hepatology, 54(6), 1230-1236 (2010-12-15)
Previous studies have demonstrated that 3,5-L-diiodothyronine (T(2)) is able to prevent lipid accumulation in the liver of rats fed a high-fat diet. Whether this effect is due to a direct action of T(2) on the liver has not been elucidated.
関連コンテンツ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）